-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Diagnosis of invasive fungal infections (IFI) in the lungs of children with cancer is challenging.
consensus criteria developed in 2008 state that bronch pipe ablister irrigation (BAL) results cannot be diagnosed.
video-assisted thoracic laparoscopic pulmonary biopsy (VATS-biopsy) has been increasingly used to assist in the assessment of these children's IFIs.
retrospective analysis to assess the impact of BAL and VATS-biopsy results on IFI management in children with cancer patients, the results of which were published online in J Pediatr Hematol Oncol.
study was included in an independent children's hospital for all oncology patients who received VATS-biopsies and/or BAL assessments within 9 years.
results are management changes in the use of antifellar therapy based on diagnostic procedures, fungal culture results, lung imaging and serological markers.
results, a total of 102 patients received 122 IFI diagnostic evaluations.
91 job evaluations included only BAL, 17 involved VATS-biopsy and 14 included both BAL and VATS-biopsy.
rate of VATS-biopsy (38.7%) was better than that of BAL (27.6%).
in 14 cases with simultaneous VATS-biopsies and BAL tests, the results were poor.
of the work, 12 children were confirmed as IFI, 29 were likely and 52 were likely.
3 times more likely to continue antifellar treatment in patients with a high risk of IFI, and 12.7 times more likely to be confirmed.
, the results suggest that VATS-biopsy may be a more useful diagnostic aid in IFI diagnosis in children with immunodeficiency on the basis of low BAL diagnosis rates.
.